Combination of Xeloda and Taxol is an effective therapy for women with metastatic breast cancer. New research from US Oncology Network and the University of North Carolina has recently reported that the combination of Xeloda (capecitabine) and Taxol is an effective and tolerable regimen for initial therapy of women with metastatic breast cancer. Women who were HER-2 negative were not included in the study. This is a phase II study and it is reported in the latest issue of the Journal of Clinical Oncology.

In this study the scientists reviewed 55 patients who were newly diagnosed metastatic breast cancer. These patients received oral Xeloda and weekly Taxol. Patients who had HER-2 positive tumors were not included in the study.

No patient had a complete response, however percent; of patients achieved a partial response. When stable disease is also taken into account 65 percent of patients derived benefit for the therapy. On average the response lasted for 10 months and median survival was 17 months.

From these findings the scientists have concluded that Xeloda plus Taxol is an effective, well-tolerated, and fairly convenient therapy combination as initial treatment for women with metastatic breast cancer.

Posted by: Betsy

---